Company Focus
Icon
Latest Icon News
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Related News
Insights
Company Spotlight
USA-based KalVista Pharmaceuticals is a protease inhibitor specialist.
Latest News & Features of interest to Icon
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). 26 June 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the trade name for Neffy in the European Union) in Germany. 26 June 2025
Biotechnology
US biotech PTC Therapeutics’ (Nasdaq: PTCT) Sephience (sepiapterin) has been granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Biosimilars
Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Bayer’s Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the commercialization of the product in the USA and Canada. 25 June 2025
Pharmaceutical
Health and Human Services Secretary Robert F Kennedy Jr came under heavy scrutiny from Democratic lawmakers during a heated budget hearing on Capitol Hill, as concerns mounted over his handling of vaccine policy, sweeping agency cuts, and what some members described as a disregard for transparency and scientific integrity. 25 June 2025
Pharmaceutical
Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). 24 June 2025
Biotechnology
Revolution Medicines, a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma on $2 billion in flexible funding to support the former company’s independent global development and commercialization strategy and operations. 24 June 2025
Latest In Brief for Icon
Pharmaceutical
Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration. 7 July 2025
Latest Relevant Ones To Watch News
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
30 June 2025
17 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze